First human trial launches for experimental cancer drug targeting tough GI tumors
NCT ID NCT06500052
Summary
This early-stage study is testing a new drug called BL-M17D1 in adults with advanced gastrointestinal cancers and other solid tumors that have a specific marker called HER2. The main goal is to find the safest dose and see how the body processes the drug. Researchers will also check for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.